CTOs on the Move

Fulton Co. Emergency Medical Association

www.fcema.com

 
Fulton Co. Emergency Medical Association is a Canton, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.fcema.com
  • 225 W Walnut St
    Canton, IL USA 61520
  • Phone: 309.647.5147

Executives

Name Title Contact Details

Similar Companies

APA Service Center

APA Service Center is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Healthnation

Healthnation, Inc. is a Lisle, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Management Services On-Call

Management Services On-Call is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accolade

We`re the only on-demand healthcare concierge for employers, health plans and health systems. Join our customers who experience industry-leading engagement levels, satisfaction scores unseen in health care, better health outcomes, and substantial medical cost savings of more than 10 percent. Our team of compassionate, trusted professionals, supported by breakthrough science and technologies guide consumers through the healthcare system in a deeply personalized manner. We`ve been recognized as one of the nation`s 25 most promising companies by Forbes magazine, the fastest-growing private healthcare company by Inc. 500, and a top workplace by multiple news publications.

Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.